Novavax Resets Its Profitability Timing Around Sanofi's 2029 U.S. Flu-COVID Launch Target
The CFO tied the timing to a $225 million milestone and said $200 million in nearer-term Sanofi payments support cash into 2029.
Novavax, which develops vaccines built on its Matrix-M adjuvant, is moving its timeline for non-GAAP profitability to match new word from partner Sanofi on a U.S. flu-COVID combination shot, Chief Financial Officer Jim Kelly said on the company's third-quarter earnings call Thursday. A U.S. launch would trigger a $225 million milestone payment, which Kelly called a primary contributor to the timing.
A $225 million swing factor
Kelly, the company's executive vice president and CFO, said Sanofi confirmed it intends to start a U.S. late-stage trial of the combination vaccine in 2027, with a potential U.S. launch in 2029. "We are updating our non-GAAP profitability timing expectations" to align with that information, he said.
Chief Executive John Jacobs said Novavax has no access to Sanofi's detailed plans or timelines and relies on its public statements and confirmations. Chief Strategy Officer Elaine O'Hara added that Sanofi's expected timelines depend on its later updates and the FDA pathway.
Asked by a Bank of America analyst how much a 2029 breakeven depends on the launch versus cost cuts, Kelly said the milestone is "not the only mechanism." He pointed to growing royalties on Nuvaxavid, partner milestones, and a target of $150 million to $200 million in non-GAAP R&D and SG&A spending by 2028.
Cash runway and a raised revenue outlook
Kelly said near-term Sanofi milestones totaling $200 million support a cash runway into 2029. Novavax ended the quarter with $676 million in cash and accounts receivable.
Third-quarter revenue was $68 million, against $70 million a year earlier, and the net loss narrowed to $31 million from $202 million. The prior-year quarter included $126 million of non-cash charges tied to asset impairments and debt extinguishment. Combined GAAP R&D and SG&A fell 41% year over year.
Novavax raised its 2026 revenue framework by $145 million to $400 million at the midpoint, within a $385 million to $415 million range. A $125 million milestone from the start of Sanofi's European phase 3 trial accounts for most of the increase.
Sanofi's partnership and the 2027 plan
Novavax licenses and supplies Matrix-M to partners and sells COVID-19 vaccine doses; Sanofi now leads commercialization of Nuvaxavid. O'Hara said the Sanofi agreement has generated over $1 billion in revenue for Novavax.
The company expects a $75 million tech-transfer milestone from Sanofi in the third quarter of 2027. To reach its 2028 target, Kelly said, headcount would fall below half the first-quarter 2026 level. Novavax is also exploring cutting its operating footprint by more than half, which could bring non-cash fixed-asset write-offs of up to $35 million during 2027.
Shares were down 10.05% at $9.58 in Thursday trading, according to market data from the session.
Sanofi's targeted 2027 start of its U.S. combination-vaccine trial is the next marker for the $225 million milestone, and the $75 million tech-transfer payment is expected in the third quarter of 2027.
Sources
- Novavax stock gains after Q3 beat, guidance hike (NVAX:NASDAQ) | Seeking Alpha — seekingalpha.com
- Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates — Yahoo Finance
- Novavax: Q3 Earnings Snapshot – WTOP News — wtop.com
- Novavax: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Novavax: Q3 Earnings Snapshot | king5.com — Associated Press